STRATEGIES TO EXTEND PLATELET STORAGE

这些研究的主要目的是确定血小板(凹坑)是否可以保存更长时间 而不是目前许可的5天。此外，窖藏的持续时间取决于窖藏的类型吗 正在储存的产品(分离坑、从富坑血浆(PRP)或从Buffy制备的坑精矿 大衣(BC)、储存前汇集的PRP窖浓缩物或病原菌减量分离或BC坑)，以及 用于存储的介质；即等离子体或存储溶液。将被提出的四个关键问题-- 在我们的研究中有：1)用分离程序采集坑口的方法与用预取的方法相比是否- 采自全血的酒窖浓缩物会不会影响保存期？2)酒窖储藏前的堆积是否会影响保存期？ 浓度影响坑的生存能力？3)坑的储存方案是否允许坑的存储时间比坑的存储时间长？ 血浆？；以及4)病原菌减少的凹坑可以与非病原菌一样长时间保存吗？ 减少坑？尽管将进行体外试验来记录贮藏后的坑口计数以及 一系列测定贮藏后贮藏功能、新陈代谢和细胞凋亡、贮藏后品质的方法 延长的储存坑将基于对正常志愿者和血小板减少症的活体测量 病人。具体地说，放射性标记的坑恢复和延长储存的自体的存活测量 正常志愿者的窖藏将被用来确定所有类型的窖藏产品的储藏后的窖藏活力 储存在等离子体中，而不是存储溶液。对于储存超过8天和/或储存的窖池 在储存液中，血小板减少患者的输血研究将被用来评估PIT的生存能力。 通过测量输血后捐献者凹陷放射性标记的恢复和存活率来评估其生存能力。另一种选择- 具体来说，患者对输血后的供血坑的反应将通过测量输血后的供血坑- 排泄量、修正后的计数增量和下一次输血的天数。PIT功能(即止血)如下 延长储存的供体坑的输血将通过坑计数与出血时间的测量来监测- 以及放射性铬标记的粪便失血研究。 在这些研究的结论中，我们应该知道每种类型的坑可以在血浆中保存多长时间 或者等离子体Lyte，每种类型的坑的相对优点，以及扩展的存储坑是否都是可行的 当给血小板减少的患者使用时，它是有效的。

The primary objective of these studies is to determine whether platelets (pits) can be stored for longer than the currently-licensed 5 days. Furthermore, does the duration of pit storage depend on the type of pit product being stored (apheresis pits, pit concentrates prepared from pit-rich plasma (PRP), or from buffy coats (BC), pre-storage pooled PRP pit concentrates, or pathogen-reduced apheresis or BC pits), and the medium used for storage; i.e., plasma or a storage solution. The four critical questions that will be ad- dressed in our studies are: 1) does the method of pit collection using apheresis procedures versus prepar- ing pit concentrates from whole blood influence storage duration?; 2) does pre-storage pooling of pit con- centrates affect pit viability?; 3) do pit storage solutions allow pits to be stored longer than pits stored in plasma?; and 4) can pathogen-reduced pits be stored for extended time periods similar to non-pathogen reduced pits? Although in vitro tests will be performed to document post-storage pit counts as well as a va- riety of assays to determine post-storage pit function, metabolism and apoptosis, the post-storage quality of the extended stored pits will be based on in vivo measurements in normal volunteers and thrombocytopenic patients. Specifically, radiolabeled pit recovery and survival measurements of extended stored autologous pits in normal volunteers will be used to determine post-storage pit viability for all types of pit products stored in plasma versus a storage solution. For pits that are stored for longer than 8 days and/or are stored in a storage solution, transfusion studies in the thrombocytopenic patients will be used to evaluate pit viabil- ity by measuring the radiolabeled recovery and survival of the donors' pits following transfusion. Alterna- tively, patient responses to transfused donor pits will be determined by measuring post-transfusion pit in- crements, corrected count increments, and days-to-next transfusion. Pit function (i.e., hemostasis) following the transfusion of extended stored donor pits will be monitored by pit count versus bleeding time measure- ments and by radiochromium-labeled stool blood loss studies. At the conclusion of these studies, we should know how long each type of pits can be stored in plasma or Plasmalyte, the relative merits of each type of pits, and whether the extended stored pits are both viable and functional when given to thrombocytopenic patients.